A detailed history of Epoch Investment Partners, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Epoch Investment Partners, Inc. holds 1,161,106 shares of BMY stock, worth $67.1 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
1,161,106
Previous 1,074,685 8.04%
Holding current value
$67.1 Million
Previous $44.6 Million 34.63%
% of portfolio
0.28%
Previous 0.21%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $3.43 Million - $4.47 Million
86,421 Added 8.04%
1,161,106 $60.1 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $6.41 Million - $8.43 Million
159,140 Added 17.38%
1,074,685 $44.6 Million
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $5.5 Million - $6.24 Million
-114,632 Reduced 11.13%
915,545 $49.7 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $4.66 Million - $5.56 Million
96,193 Added 10.3%
1,030,177 $52.9 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $1.84 Million - $2.06 Million
-31,819 Reduced 3.29%
933,984 $54.2 Million
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $30.3 Million - $33.6 Million
474,907 Added 96.74%
965,803 $61.8 Million
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $27 Million - $30.6 Million
410,966 Added 514.16%
490,896 $34 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $31,911 - $37,787
-466 Reduced 0.58%
79,930 $5.75 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $565 - $334,484
-4,353 Reduced 5.14%
80,396 $5.72 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $65,285 - $71,902
899 Added 1.07%
84,749 $6.53 Million
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $5.16 Million - $6.18 Million
83,850 New
83,850 $6.12 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Epoch Investment Partners, Inc. Portfolio

Follow Epoch Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Epoch Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Epoch Investment Partners, Inc. with notifications on news.